Literature DB >> 27846402

Focal therapy in prostate cancer: A review of seven common controversies.

Edward J Bass1, Hashim U Ahmed2.   

Abstract

Radical treatments such as prostatectomy and radiotherapy have demonstrated success in terms of biochemical and disease-specific survival for localised prostate cancer. However, whilst the end goal of any cancer treatment is to control or cure disease it must also do so by minimising any side effects that may be experienced by the patient. Focal therapy as a concept aims to redress this established therapeutic ratio by treating areas of the prostate affected by significant disease as opposed to treating the entire gland. However, there are a number of common criticisms of focal therapy - we deem the seven sins - that require further interrogation. Copyright Â
© 2016. Published by Elsevier Ltd.

Entities:  

Keywords:  Arguments against; Arguments for; Focal therapy; Prostate cancer

Mesh:

Year:  2016        PMID: 27846402     DOI: 10.1016/j.ctrv.2016.07.004

Source DB:  PubMed          Journal:  Cancer Treat Rev        ISSN: 0305-7372            Impact factor:   12.111


  13 in total

Review 1.  Focal therapy for localized prostate cancer in the era of routine multi-parametric MRI.

Authors:  M J Connor; M A Gorin; H U Ahmed; R Nigam
Journal:  Prostate Cancer Prostatic Dis       Date:  2020-02-12       Impact factor: 5.554

Review 2.  Image-Guided Percutaneous Ablation for Primary and Metastatic Tumors.

Authors:  Arian Mansur; Tushar Garg; Apurva Shrigiriwar; Vahid Etezadi; Christos Georgiades; Peiman Habibollahi; Timothy C Huber; Juan C Camacho; Sherif G Nour; Alan Alper Sag; John David Prologo; Nariman Nezami
Journal:  Diagnostics (Basel)       Date:  2022-05-24

Review 3.  The prostate cancer focal therapy.

Authors:  Filippo Pesapane; Francesca Patella; Enrico Maria Fumarola; Edoardo Zanchetta; Chiara Floridi; Gianpaolo Carrafiello; Chloë Standaert
Journal:  Gland Surg       Date:  2018-04

Review 4.  All change in the prostate cancer diagnostic pathway.

Authors:  Derek J Lomas; Hashim U Ahmed
Journal:  Nat Rev Clin Oncol       Date:  2020-02-28       Impact factor: 66.675

Review 5.  Consensus statements on the management of clinically localized prostate cancer from the Hong Kong Urological Association and the Hong Kong Society of Uro-Oncology.

Authors:  Wai-Kit Ma; Darren Ming-Chun Poon; Chi-Kwok Chan; Tim-Wai Chan; Foon-Yiu Cheung; Lap-Yin Ho; Eric Ka-Chai Lee; Angus Kwong-Chuen Leung; Simon Yiu-Lam Leung; Hing-Shing So; Po-Chor Tam; Philip Wai-Kay Kwong
Journal:  BJU Int       Date:  2019-02-05       Impact factor: 5.588

6.  Treatment decision satisfaction and regret after focal HIFU for localized prostate cancer.

Authors:  Niklas Westhoff; Ramona Ernst; Karl Friedrich Kowalewski; Laura Schmidt; Thomas Stefan Worst; Maurice Stephan Michel; Jost von Hardenberg
Journal:  World J Urol       Date:  2020-06-12       Impact factor: 4.226

Review 7.  Multi-parametric MRI imaging of the prostate-implications for focal therapy.

Authors:  James S Wysock; Herbert Lepor
Journal:  Transl Androl Urol       Date:  2017-06

Review 8.  Targeting the cancer lesion, not the whole prostate.

Authors:  Nishant Bedi; Deepika Reddy; Hashim U Ahmed
Journal:  Transl Androl Urol       Date:  2020-06

9.  A Multicentre Study of 5-year Outcomes Following Focal Therapy in Treating Clinically Significant Nonmetastatic Prostate Cancer.

Authors:  Stephanie Guillaumier; Max Peters; Manit Arya; Naveed Afzal; Susan Charman; Tim Dudderidge; Feargus Hosking-Jervis; Richard G Hindley; Henry Lewi; Neil McCartan; Caroline M Moore; Raj Nigam; Chris Ogden; Raj Persad; Karishma Shah; Jan van der Meulen; Jaspal Virdi; Mathias Winkler; Mark Emberton; Hashim U Ahmed
Journal:  Eur Urol       Date:  2018-06-28       Impact factor: 20.096

10.  MRI-guided, transrectal, intraprostatic steam application as potential focal therapeutic modality for prostatic diseases in a large animal translational model: A feasibility follow-up study.

Authors:  Adriano Wang-Leandro; Florian Willmitzer; Agnieszka Karol; Beat Porcellini; Peter Kronen; Emile M Hiltbrand; Daniel Rüfenacht; Patrick R Kircher; Henning Richter
Journal:  PLoS One       Date:  2019-12-23       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.